"We believe that the strength of this application is that deramiocel has shown in multiple clinical trials attenuation of the cardiac implications of DMD. We look forward to working with the FDA ...

Shares of Capricor Therapeutics CAPR gained 8.4% on Thursday following the completion of the submission of a biologics license application (BLA) to the FDA seeking full approval for deramiocel to ...

“We believe that the strength of this application is that deramiocel has shown in multiple clinical trials attenuation of the cardiac implications of DMD. We look forward to working with the FDA ...

Linda Marbán, Ph.D., the Chief Executive Officer of Capricor, emphasized the significance of this milestone, highlighting the potentially transformative impact of deramiocel on individuals grappl ...

seeking full approval for deramiocel, an investigational cell therapy, to treat patients diagnosed with Duchenne muscular dystrophy, DMD, cardiomyopathy. The full submission of the rolling BLA was ...

These trials have indicated that deramiocel may help manage cardiac complications associated with DMD, a genetic disorder characterized by muscle degeneration and premature death. The company has ...

These trials have indicated that deramiocel may help manage cardiac complications associated with DMD, a genetic disorder characterized by muscle degeneration and premature death. The company has ...

Cell therapy developer Capricor Therapeutics (NASDAQ:CAPR) announced Thursday the completion of the U.S. marketing application for its lead candidate, deramiocel, for patients with Duchenne ...